NextCure (NXTC) Change in Account Payables (2018 - 2026)
NextCure (NXTC) posted quarterly Change in Account Payables of $1.1 million for Q1 2026, up 140.47% year-over-year from $440394.6 in Q1 2025, and up 378.68% quarter-over-quarter from -$380000.0 in Q4 2025.
NextCure (NXTC) Change in Account Payables (2018 - 2026) Analysis & Trends
NextCure's Change in Account Payables history runs 9 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 140.47% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $334000.0 (up 119.03% YoY), while the FY2025 annual figure was -$3.3 million, down 210.55% from the prior year.
- Change in Account Payables for Q1 2026 stood at $1.1 million, up from -$380000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $2.4 million in Q4 2022, with the low at -$2.6 million in Q1 2025.
- The 5-year median for Change in Account Payables is -$192000.0 (2025), against an average of $66352.9.
- Peak annual rise in Change in Account Payables reached 739.71% in 2024, while the deepest fall reached 592.89% in 2024.
- NextCure's Change in Account Payables stood at $2.4 million in 2022, then tumbled by 111.23% to -$272000.0 in 2023, then soared by 739.71% to $1.7 million in 2024, then tumbled by 121.84% to -$380000.0 in 2025, then surged by 378.68% to $1.1 million in 2026.
- Business Quant data shows NXTC's Change in Account Payables at $1.1 million in Q1 2026, -$380000.0 in Q4 2025, and -$153000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | -492,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -492,000.00 |
| Jun 30, 2026 | -492,000.00 |
| Mar 31, 2026 | 1.06 Mn |
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | -380,000.00 |
| Dec 31, 2025 | -380,000.00 |
| Sep 30, 2025 | -153,000.00 |
| Sep 30, 2025 | -153,000.00 |
| Jun 30, 2025 | -192,000.00 |
| Jun 30, 2025 | -192,000.00 |
| Mar 31, 2025 | -2.62 Mn |
| Mar 31, 2025 | -2.62 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Dec 31, 2024 | 1.74 Mn |
| Sep 30, 2024 | -1.46 Mn |
| Sep 30, 2024 | -1.46 Mn |
| Jun 30, 2024 | 584,000.00 |
| Jun 30, 2024 | 584,000.00 |
| Mar 31, 2024 | 2.16 Mn |
| Mar 31, 2024 | 2.16 Mn |